UnitedHealth, FTC reach proposed settlement in insulin case
Emily Olsen / healthcaredive - The tentative deal comes months after CVS Health reached a proposed settlement in the lawsuit alleging major pharmacy benefit managers are inflating insulin costs.
AI Summary: UnitedHealth/Optum Rx reached a proposed settlement with the FTC over alleged anti-competitive insulin rebate and pricing practices, including terms to resolve claims that rebates harmed competition and patients. The agreement would curb disputed pharmacy benefit manager conduct and could reshape how insulin discounts are negotiated and passed through to consumers.
Related Stories
Bill would let patient drug spending count toward insurance deductibles / 1 month
340B discounts face reform as profits outpace patient benefit / 7 wks
AbbVie sues HHS over 340B patient definition and guidance / 2 months
CVS sues Tennessee over PBM‑pharmacy separation law / 18 days
Optum Rx launches transparent PBM model, delinking drug prices from fees / 4 wks
Senate Democrats unveil plan to cut health costs and expand coverage / 2 months
Optum Rx/Caremark and FTC edge toward settlement in insulin case / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Government Policy, Genetics, Drug Development, Public Health and look for the RSS link.
StackHealth Time Machine